Australia markets closed

    -21.70 (-0.29%)

    -0.0012 (-0.17%)
  • ASX 200

    -10.70 (-0.15%)
  • OIL

    +0.26 (+0.40%)
  • GOLD

    -4.90 (-0.27%)

    -1,624.62 (-2.00%)
  • CMC Crypto 200

    -27.39 (-1.86%)

ANANDA Scientific’s Liquid Structure™ Cannabidiol (CBD) to Be Clinically Evaluated for Opioid Use Disorder

·2-min read

GREENWOOD VILLAGE, Colo. & NEW YORK, October 19, 2021--(BUSINESS WIRE)--ANANDA Scientific Inc., a biotech pharma company, announced a clinical trial to evaluate Nantheia™ ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary Liquid Structure™ delivery technology for Opioid Use Disorder. An Investigational New Drug (IND) application has been approved by the U.S. Food and Drug Administration (FDA) for this trial.

Pre-clinical and initial clinical studies show ANANDA’s Liquid Structure technology (licensed from Lyotropic Delivery Systems (LDS) Ltd., Jerusalem, Israel), enhances the effectiveness and stability of CBD. Nantheia™ ATL5 is an oral product with 100mg of CBD per softgel capsule and is ANANDA’s investigational drug utilizing Liquid Structure™ technology.

"This clinical trial with Nantheia™ ATL5 has the possibility to advance applications for CBD in ANANDA’s patented delivery technology in an area that could positively impact the lives of a large number of people suffering from opioid addiction. Opioids are a huge driver of overdose deaths in the U.S. and a non-addictive therapy is a significant unmet need," said Sohail R. Zaidi, ANANDA’s President.

This trial is being conducted at the Icahn School of Medicine at Mount Sinai led by principal investigator Yasmin L Hurd, Ph.D, the Ward-Coleman Chair of Translational Neuroscience and the Director of the Addiction Institute at Mount Sinai. Funding for this trial was awarded to Dr. Hurd by the National Institute on Drug Abuse (NIDA). ( Identifier NCT 05203070).


ANANDA is a leading research-focused biotech company pioneering high-caliber clinical studies evaluating therapeutic indications for cannabinoids such as PTSD, Radiculopathic Pain, Anxiety and Opioid Use Disorder. The company employs patented delivery technologies to make cannabinoids and other plant derived compounds highly bioavailable, water soluble, and shelf-life stable and focuses on producing effective, premium quality pharmaceutical products. Consistent with its strong research-based data, the company also has a growing pipeline of nutraceutical over-the-counter products. The company has successfully launched these products in the US, Australia, and the UK, with expansion into additional markets such as the EU, China, Africa and other countries in Asia planned for the future. The company is expanding its research base through multiple sponsored research agreements with universities to diversify its technology portfolio.

View source version on


ANANDA Scientific Media Relations
Christopher Moore

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting